Powering Life Sciences and Health Innovation - A Global AI Alliance from Singapore

Singapore, 26 August 2025 – Nanyang Biologics (NYB) successfully launched the inaugural AI4Life Summit 2025 at The Fullerton Hotel, bringing together global technology leaders NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix to advance Singapore’s position as a hub for AI-powered drug discovery and healthcare innovation.

‍

The Summit marked a historic milestone with the signing of a Memorandum of Understanding (MoU) between NYB, NVIDIA, HPE, and Equinix – establishing a global alliance to accelerate biomedical AI. This collaboration will focus on building the world’s largest natural compound library, developing scalable AI platforms for drug discovery, and creating secure, enterprise-grade infrastructure for healthcare innovation.

‍

Throughout the afternoon, keynote sessions by leaders from NYB, NVIDIA, HPE, and Equinix highlighted the potential of AI to transform therapeutic discovery, from faster predictive modeling to global-ready infrastructure for biomedical data. The MoU signing further reinforced the commitment of all four organizations to deliver impactful healthcare solutions through advanced technology and cross-sector collaboration.

‍

The Summit concluded with a panel discussion on “Strategic Infrastructure for Therapeutic Innovation,” moderated by Giang Nguyen, CTO of NYB, alongside Dennis Ang (NVIDIA), Jason Ong (HPE), and Eric Hui (Equinix). The panel emphasized the importance of scalable infrastructure, responsible AI adoption, and global collaboration in shaping the future of healthcare. Panelists also highlighted Singapore’s pivotal role in driving this transformation through the combined ecosystem of NYB, NVIDIA, HPE, and Equinix.

‍

Reflecting on the Summit, Dr. Roland Ong, Chairman of Nanyang Biologics, said: “The AI4Life Summit is not just a gathering of minds, but the launchpad for a bold vision to position Singapore at the forefront of AI-driven healthcare innovation. By partnering with global technology leaders, we are creating a collaborative ecosystem that will accelerate drug discovery and unlock new therapeutic possibilities for patients worldwide.”

‍

As the demand for next-generation drug discovery platforms grows rapidly across Southeast Asia, North America, and Europe, this partnership demonstrates how strategic alliances between biotech and technology leaders can transform research into real-world healthcare impact.

‍

–

‍

About Nanyang Biologics (NYB)

Singapore-headquartered Nanyang Biologics is a biotech company using AI and biological data to understand drug-target interactions in disease pathways. Through its AI platform Vecura and extensive natural compound libraries, NYB identifies promising therapeutic molecules and optimizes them for effectiveness. Leveraging advanced machine learning techniques, NYB accelerates the discovery of next-generation treatments for cancer, chronic diseases, and wellness applications.

‍

About NVIDIA

NVIDIA (Nasdaq: NVDA) is a global leader in accelerated computing. Its groundbreaking GPU and AI platforms power breakthroughs in genomics, medical imaging, biomolecular research, and drug discovery. NVIDIA’s technologies enable researchers and enterprises to accelerate scientific discovery and deliver next-generation healthcare solutions at scale.

‍

About Hewlett Packard Enterprise (HPE)

Hewlett Packard Enterprise (NYSE: HPE) is the edge-to-cloud company that helps organizations accelerate outcomes by unlocking value from all of their data, everywhere. In life sciences and healthcare, HPE provides secure, high-performance computing, hybrid cloud solutions, and enterprise-grade AI infrastructure to support the entire pipeline of biomedical innovation and drug discovery.

‍

About Equinix

Equinix, Inc. (Nasdaq: EQIX) is the world’s digital infrastructure company. Its global platform of interconnected data centers enables organizations to securely move and analyze data across borders. In healthcare and life sciences, Equinix provides the trusted connectivity and digital ecosystems that support real-time collaboration, accelerating biomedical research and therapeutic innovation worldwide.